It can also support anti-tumor immune responses in CRC patients by decreasing the production of neutrophil extracellular traps (NETs) released from tumor-associated neutrophils (TANs), thereby allowing the CD3+CD8+ lymphocytes to infiltrate the tumor [38]. Here, CD8A is linked to neoplasm.